U.S. Professional Services Stock News

In March 2026, Qualys, Inc. launched Agent Val within its Enterprise TruRisk Management platform, introducing AI-led exploit validation and autonomous risk remediation for security teams’ Risk Operations Centers. By shifting vulnerability management from assumption-based prioritization to evidence-backed validation, Agent Val aims to cut remediation noise, sharpen focus on truly exploitable risks, and give organizations clearer proof of cyber risk reduction. Next, we’ll examine how Agent...

Walt Disney (NYSE:DIS) has reportedly terminated a planned $1b AI partnership with OpenAI that would have licensed over 200 characters for AI generated video content. The cancellation, described as abrupt and unexpected for Disney, highlights financial and operational risks around large scale AI and media collaborations. At the same time, multiple Disney directors have recently purchased company shares, signaling fresh internal views on the company’s prospects. Disney shares most recently...

Starbucks (NasdaqGS:SBUX) has completed a major China joint venture with Boyu Capital, altering the ownership structure of its China retail operations. The company is rolling out new U.S. employee programs, including performance based bonuses, weekly pay, and expanded digital tipping for baristas. These changes affect one of Starbucks' most important international markets and reshape its approach to labor in the U.S. Starbucks shares last closed at $90.37, with mixed recent returns that...

CRISPR Therapeutics (CRSP) has caught investor attention after becoming the first gene editing peer to generate commercial revenue from its approved therapy Casgevy, supported by Vertex Pharmaceuticals and a sizable cash cushion for upcoming trials. See our latest analysis for CRISPR Therapeutics. CRISPR Therapeutics’ recent news on Casgevy and upcoming trial milestones comes after a sharp 1 year total shareholder return of 51.59%, even as the 30 day share price return of 14.73% and 90 day...

Exxon Mobil (XOM) is back on many investors’ screens after a recent move in its share price, with the stock posting a return over the past month and a stronger gain over the past three months. See our latest analysis for Exxon Mobil. Even with a 2.9% 7 day share price pullback, Exxon Mobil’s recent 30 day share price return of 5.8% and year to date share price return of 31.0% suggest momentum has been strong. The 1 year total shareholder return of 47.8% and 5 year total shareholder return of...

Nike (NKE) just reported fiscal Q3 results that topped earnings expectations, but the real shock for investors came from management’s outlook, which calls for a 2% to 4% revenue decline next quarter. See our latest analysis for NIKE. The guidance reset has fed straight into the share price, with Nike now trading at US$44.19 after a 30.17% year to date share price decline and a 64.34% five year total shareholder return loss, signaling fading momentum as investors reassess execution risk and...

In March 2026, the Public Health Advocacy Institute filed a landmark product liability lawsuit in Pennsylvania against DraftKings, FanDuel, Genius Sports, and the NFL, alleging their online platforms use AI‑driven microbetting features and intensive promotions that foster gambling addiction and violate consumer protection laws. This case sharpens focus on how online sportsbooks monetize live in-game microbets and VIP-style inducements, raising questions about product design, data use, and...

In March 2026, Amprius Technologies, Inc. announced it had secured a US$21,000,000 purchase order from a new premier electric mobility customer in China for its high-energy-density SiCore cylindrical cells, to be used in light electric vehicles such as scooters, three-wheelers, and motorcycles. An interesting aspect of this deal is that it extends Amprius’ silicon-anode battery technology beyond drones and aviation into the growing light electric vehicle market, potentially broadening its...

What Hubbell's Recent Share Move Signals for Investors Hubbell (HUBB) has attracted fresh attention after a recent pullback of about 1% in the latest session, even as its shares show gains over the past week, month, and past three months. See our latest analysis for Hubbell. Following the latest 1.23% one day share price decline to US$494.25, Hubbell’s 6.74% year to date share price return and 55.71% one year total shareholder return indicate momentum that has been building rather than...

Conagra Brands (CAG) just reported third quarter results that topped revenue expectations but narrowly missed earnings per share forecasts, while also tightening 2026 guidance and highlighting ongoing pressure from input costs and softer margins. See our latest analysis for Conagra Brands. The latest results land against a weak share price backdrop, with a 30 day share price return of 17.09% and a 1 year total shareholder return loss of 36.88%, which points to fading longer term momentum...

In March 2026, Eisai and Nuvation Bio reported that the European Medicines Agency validated their Marketing Authorisation Application for taletrectinib to treat advanced ROS1-positive non-small cell lung cancer, following existing approvals in the US, China and Japan. This regulatory milestone could broaden taletrectinib’s geographic reach under Eisai’s licensing deal, potentially deepening Nuvation Bio’s role in targeted lung cancer treatment across Europe and other Eisai territories. We’ll...

If you are wondering whether Ventas at around US$83.27 offers fair value or a potential mismatch between price and fundamentals, this article walks through the key signals to watch. The stock has returned 0.7% over the last 7 days, 7.7% year to date and 22.9% over the past year, alongside a 3 year return of 115.3% and a 5 year return of 79.6%, which raises questions about how much optimism is already in the price. Recent coverage has focused on Ventas as a major health care REIT, with...

Why Ford Motor (F) is on investors’ radar today Ford Motor (F) continues to draw attention as investors weigh its recent share performance against the company’s scale, with a market value of about US$46.8b and annual revenue of roughly US$187.3b. See our latest analysis for Ford Motor. Recent share price moves have been softer, with a 30 day share price return of 8.66% and a year to date share price return of a 13.04% decline, while the 1 year total shareholder return of 27.84% points to...

Nvidia’s US$2b investment in Marvell Technology (MRVL), together with a deep AI infrastructure partnership, puts Marvell’s networking, custom accelerators and silicon photonics at the heart of Nvidia’s expanding data center and telecom AI systems. See our latest analysis for Marvell Technology. The Nvidia partnership has arrived on top of strong momentum, with a 30 day share price return of 38.19% and a 1 year total shareholder return of 93.15%. The 5 year total shareholder return of 116.66%...

In late March 2026, Open Quantum Design announced a new open-source Error Correction Working Group with QuScript and Western Digital to advance quantum error correction on its full-stack trapped-ion quantum computer, aiming to develop and showcase fault-tolerant protocols. This collaboration taps Western Digital’s long history in data reliability and error correction, potentially extending its expertise from classical storage into emerging quantum computing infrastructure. We’ll now...

Over the past week, Lam Research has been in the spotlight as investors, analysts and funds highlighted its strong AI-driven semiconductor equipment demand, recent fiscal Q2 2026 outperformance, and deepening role in high-bandwidth memory and advanced packaging supply chains. At the same time, contrasting analyst views on margin risks, geopolitical supply concerns, and an increased stake from Ray Dalio’s Bridgewater are creating a more complex picture of Lam’s risk‑reward balance. Next,...

If you are wondering whether Independent Bank at around US$76.78 is still priced attractively or has already run ahead of itself, the valuation picture is the key question to focus on. Over the past year the stock has returned 38.6%, with a 4.9% gain year to date, a 2.3% move over the last week and a 3.4% decline over the last month, which may signal shifting views on its growth potential or risk profile. Recent coverage has highlighted Independent Bank in the context of broader regional...

Wondering whether Allegion's current share price reflects its true worth, or if the market is mispricing the stock right now. The shares closed at US$141.06, with returns of a 3.2% decline over 7 days, a 10.9% decline over 30 days, and a 12.3% decline year to date, set against a 12.4% gain over the past year and 47.9% over 3 years. Recent coverage has focused on Allegion as a steady building products business, with investors watching how its security and access solutions fit into long term...

For investors considering whether Compañía de Minas BuenaventuraA is still reasonably priced after its strong run, this article looks at what the current share price might be implying about the stock's value. The stock recently closed at US$36.41, with returns of 12.2% over the last 7 days, a 6.1% decline over 30 days, 27.4% year to date and 155.5% over the past year, as well as a very large gain over 3 years and 262.6% over 5 years. Recent trading has been influenced by ongoing investor...

Lattice Semiconductor recently reported a past quarter in which revenue exceeded analyst expectations, inventories improved, and management pointed to strong contributions from AI and data center demand. The company’s recognition for post-quantum cybersecurity FPGAs and a reinforced role alongside AI infrastructure providers highlights how it is tying its low-power chips to some of the most security-sensitive and fast-growing computing workloads. With these results underscoring accelerating...

AbCellera Biologics recently outlined its evolution toward becoming a mid- to late-stage biotech at the 2026 KeyBanc Capital Markets Healthcare Forum, highlighting a clinical pipeline that includes ABCL635 in Phase 2 for non-hormonal hot flashes and ABCL575 in Phase 1 for immunological diseases. The company also underscored a cash position of roughly US$700 million and a three-year funding runway, a combination that may give it unusual flexibility to keep advancing its programs and...

Xcel Energy (XEL) is back in focus as investors look ahead to its upcoming Q1 2026 earnings call, while the company reiterates its multi year EPS outlook and a sizable US$60b grid investment plan. See our latest analysis for Xcel Energy. The share price has been firming in recent months, with an 8.11% year to date share price return and a 15.46% total shareholder return over the past year. This suggests momentum has been building as the grid investment plan, coal plant timeline revisions and...

Recent share performance in context McDonald's (MCD) has seen its share price under some pressure recently, with a 7.5% decline over the past month, while the past 3 months show a modest 1.3% gain. See our latest analysis for McDonald's. Set against a 1-year total shareholder return decline of 1.3% and a 5-year total shareholder return of 49.4%, McDonald's recent 1-month share price return decline of 7.5% suggests momentum has cooled after a stronger multi year run. If recent moves in...

Shareholders appeared unconcerned with Utah Medical Products, Inc.'s ( NASDAQ:UTMD ) lackluster earnings report last...